eRibo Pro measures both transcription and translation, providing detailed information to understand RNA biology and develop more effective RNA therapeutics.
Contact useRibo Pro provides actionable insights into the expression and translation of endogenous and transfected RNAs.
Transcription and translation are key determinants of therapeutic action and disease state progression. Our eRibo Pro assay combines RNA-Seq for gene expression with an exclusively licensed* method for ribosome profiling (Ribo-Seq), providing multidimensional insights into both transcription and translation.
Contact us*Eclipsebio is sole licensee of the Ribo-seq method covered by U.S. Patent Numbers 8,486,865, 9,284,547 and 9,677,068.
Overview
Use:
Measure transcription (RNA-Seq) and translation (ribosome profiling)
Typical species:
Human, mouse
Typical samples:
Cells, tissues
*Eclipsebio is sole licensee of the Ribo-seq method covered by U.S. Patent Numbers 8,486,865, 9,284,547 and 9,677,068.
Measure RNA expression and protein translation
Ready to start your eRibo Pro project? Contact us today.
Contact usExtract RNA
Ribosome protected footprint (RPF) and RNA-Seq libraries
are generated
Sequence
Next-generation sequencing is performed on both the RPF and RNA-Seq libraries
Analyze
Custom bioinformatics analyses determine changes in RNA expression and translation
Discover a multiomic
view of RNA biology
The following are some examples of the types of insights that eRibo Pro can provide. For our partners, we perform additional analyses to provide actionable insights for therapeutic success.
Measure changes in ribosome occupancy
Ribosome occupancy, also called translation efficiency or TE, is a relative measure of the amount of ribosomes on a given gene. This metric is often used to detect target-specific changes in translation with small molecules, or to rank mRNA vaccine candidates for optimal protein production.
Volcano plot for RNA-Seq and ribosome occupancy after treatment with Torin 1, a selective inhibitor of translation. Changes are specific to ribosome occupancy.
Identify stalled ribosomes
Ribosome stalling can lead to decreased protein production or frameshifted proteins. This makes identification of ribosome stalls critical for mRNA therapeutic development and the comprehensive evaluation of small molecule candidates. eRibo Pro provides per codon measurements of ribosome enrichment, enabling the robust identification of where ribosome stalls occur.
Browser tracks showing the PCSK9 gene. Data from samples treated with PF-846, which induces ribosome stalls on the first exon, and untreated controls are shown.
Find therapeutic off-targets
All therapeutics have a risk of off-target effects, which can halt a clinical trial. By measuring both RNA levels and translation, eRibo Pro provides a more comprehensive view of therapeutic effects, allowing developers to move to the clinic with increased confidence.
Volcano plot showing changes in RNA expression after treatment with an siRNA. Off-targets due to direct siRNA binding are highlighted in teal.